SELLAS Life Sciences Group, Inc.
SLS
$12.78
$0.423.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.77M | 12.42M | 11.15M | 12.31M | 12.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.12M | 30.36M | 27.17M | 28.04M | 28.28M |
| Operating Income | -33.12M | -30.36M | -27.17M | -28.04M | -28.28M |
| Income Before Tax | -32.46M | -29.46M | -26.86M | -25.94M | -26.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.46 | -29.46 | -26.86 | -25.94 | -26.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.46M | -29.46M | -26.86M | -25.94M | -26.26M |
| EBIT | -33.12M | -30.36M | -27.17M | -28.04M | -28.28M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.22 | -0.23 | -0.25 | -0.29 | -0.33 |
| Normalized Basic EPS | -0.13 | -0.14 | -0.15 | -0.19 | -0.21 |
| EPS Diluted | -0.22 | -0.23 | -0.25 | -0.29 | -0.33 |
| Normalized Diluted EPS | -0.13 | -0.14 | -0.15 | -0.19 | -0.21 |
| Average Basic Shares Outstanding | 611.32M | 520.70M | 435.98M | 368.70M | 328.56M |
| Average Diluted Shares Outstanding | 611.32M | 520.70M | 435.98M | 368.70M | 328.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |